All News
Early MRI Sacroiliac Improvement with JAK Inhibition
The TORTUGA trial tested filgotinib, a JAK1 inhibitor, in active ankylosing spondylitis (AS) patients and was shown to be both effective and capable of retarding sacroiliac (SI) joint erosions as early as 12 weeks.
Read Article
Can you manage FM without opioids? Study of 698 Fibromyalgia pts from a tertiary center finds 27.1% taking opioids. Opioid associated with longer Sx duration (>3 yrs), increased age, worse functional impairment & pain catastrophizing https://t.co/N1G4ZtkUE5
Links:
Dr. John Cush RheumNow ( View Tweet)
Delays in Joint Replacement as JIA Patients Reach Adulthood
https://t.co/EQNZPD8d7o
The JIA category, year of implant, and presence of complications significantly affected implant survivorship. https://t.co/yiD74AElPC
Links:
Dr. John Cush RheumNow ( View Tweet)
FDA issued Drug Safety Communication to statin manufacturers requesting they remove strong warnings against statin use during pregnancy. While statins appear in breast milk, they should not be contraindicated, if needed, during Pregnancy https://t.co/AeFwpsLMXT
Links:
Dr. John Cush RheumNow ( View Tweet)
Pfizer has another JAK inhibitor - ritlecitinib - shown to be effective (vs PBO) in alopecia areata in the Phase 2b/3 ALLEGRO trial. Ritlecitinib is also being studied in vitiligo, rheumatoid arthritis, Crohn’s & ulcerative colitis. https://t.co/ccx0eRXuTS https://t.co/fApTP7WaYU
Links:
Dr. John Cush RheumNow ( View Tweet)
IL-6 Inhibitor Safety Issues-Download now!
https://t.co/rjId76sJ64 https://t.co/QwBJNmrzBf
Links:
Dr. John Cush RheumNow ( View Tweet)
In a head to head trial Upadacitinib was superior to Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis. 24wk DBRCT, 924 pts given either UPA 30/d vsDUP 300 EOW. ESI75 response@wk16, UPA 71% vs DUP 61% https://t.co/5cOoosKyao
Links:
Dr. John Cush RheumNow ( View Tweet)
New podcast available for download!
https://t.co/5K8ejJ4jj2 https://t.co/Va66dLGrXO
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI:
Skin Involvement with HMGCR Necrotizing Myositis
The Journal of Autoimmunity reports that anti-HMRCR antibody positive, necrotizing myositis patients frequently have cutaneous lesions, more so than previously reported.
https://t.co/RR07dYIJSr https://t.co/MiaIqvMPaB
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI:
D-penicillamine Adverse events reported to FDA (1970-2020): dystonia (OR 20.52), drug hypersensitivity (OR 5.42), pancytopenia (OR 10.2), joint swelling (OR 9.07), Renal (OR 6.68), dysphagia (OR 5.05), CHF (OR 4.04), edema (OR: 3.77) https://t.co/8lmYiJo2Tz
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI:
CRESS – A New Composite Measure for Primary Sjögren's Syndrome
https://t.co/7tvjBvP3g4
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI:
JRheum review: 40–50% of psoriasis pts have psoriatic nail disease NP). NP is an important predictor of enthesitis, which is associated with the early stages of PsA https://t.co/sEuih3CSgX
Links:
Dr. John Cush RheumNow ( View Tweet)
It was a banner week at the FDA; a new drug approval you should know about; a lot of information about pregnancy & safety; and an interesting case plus a question from one of our readers submitted. This and more in this week's podcast. Let's dive in.
https://t.co/5K8ejJ4jj2 https://t.co/pqCsvYuI96
Links:
Dr. John Cush RheumNow ( View Tweet)
Veterans study gout prevalence rose from 4.2% to 5.8%, 2005 to 2014. 2014, 4.0% of all inpatient/outpatient encounters & 1.3% of hospitalizations were gout related. ULT use remained stable with 46% of gout patients receiving ULT https://t.co/Lmf2mmMddW
Links:
Dr. John Cush RheumNow ( View Tweet)
Skin Involvement with HMGCR Necrotizing Myositis
The Journal of Autoimmunity reports that anti-HMRCR antibody positive, necrotizing myositis patients frequently have cutaneous lesions, more so than previously reported.
https://t.co/RR07dYIJSr https://t.co/f4WdkRZWpM
Links:
Dr. John Cush RheumNow ( View Tweet)
Rheumatic Flares Uncommon After COVID Vax
https://t.co/fuyC50K5UF
Post-vaccination disease flares were uncommon among patients with rheumatic and musculoskeletal diseases who were inoculated against COVID-19, researchers found. https://t.co/jp0ZoRqnla
Links:
Dr. John Cush RheumNow ( View Tweet)
Study of 708 newly Dx rotator cuff disorder shows that 6 sessions of Progressive exercise was not superior to a 1 physiotherapist session in improving shoulder pain and function. Subacromial corticosteroid injection provided no long-term benefits https://t.co/Flqv286MVV
Links:
Dr. John Cush RheumNow ( View Tweet)
Study of 1821 pregnant women with autoimmune disorder. 74% used acetaminophen during pregnancy (HA, pain, injury). The highest (5th quintile use thru wk 20) acetaminophen had a modest risk (HR 1.62) of preeclampsia vs none https://t.co/DXxaSkTZs7
Links:
Dr. John Cush RheumNow ( View Tweet)
Clinical characteristics and outcomes of COVID-19 breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases https://t.co/xftj12BgzX #medRxiv
medRxiv medrxivpreprint ( View Tweet)
The Israeli data for increased mRNA-vaccination breakthrough infections and "waning immunity" is finally available
https://t.co/9j73Q7L7Nn h/t @Aiims1742
Overall 2X risk, no statistical significant difference between age groups, but trend of increase w/ age https://t.co/D4IpFm6Ydl
Eric Topol EricTopol ( View Tweet)